← 返回

人类肾癌中耗竭的瘤内 Vδ2(-) γδ T 细胞保留效应功能

英文原题:Exhausted intratumoral Vδ2(-) γδ T cells in human kidney cancer retain effector function.

查看英文原题

Exhausted intratumoral Vδ2(-) γδ T cells in human kidney cancer retain effector function.

PubMed 2023/03/16(内容时间) Nat Immunol Q1 · IF 26.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

γδ T 细胞存在于包括肿瘤在内的人体组织中,但其在介导对免疫检查点抑制的抗肿瘤反应中的功能尚不清楚。本研究表明,肾癌被 Vδ2- γδ T 细胞浸润,其中 Vδ1+ 和 Vδ1- 细胞比例相当,且与正常人组织中发现的 γδ T 细胞不同。这些肿瘤驻留的 Vδ2- T 细胞可表达耗竭 αβ CD8+ T 细胞的转录程序,以及终末 T 细胞耗竭的经典标志物,包括 PD-1、TIGIT 和 TIM-3。尽管 Vδ2- γδ T 细胞的 IL-2 产生减少,但它们仍保留细胞溶解效应分子和共刺激受体如 4-1BB 的表达。耗竭的 Vδ2- γδ T 细胞由三个不同的群体组成,这些群体缺乏 TCF7,呈克隆扩增,并表达细胞毒性分子和多种 Vδ2- T 细胞受体。人肿瘤来源的 Vδ2- γδ T 细胞在体外维持细胞毒功能和促炎细胞因子分泌。治疗前肿瘤活检中 Vδ2- T 细胞的转录程序被用于预测癌症患者随后对 PD-1 阻断的临床反应。

因此,肿瘤微环境中的 Vδ2- γδ T 细胞可促进抗肿瘤疗效。

展开英文摘要原文

Gamma delta (γδ) T cells reside within human tissues including tumors, but their function in mediating antitumor responses to immune checkpoint inhibition is unknown.

Here we show that kidney cancers are infiltrated by Vδ2 - γδ T cells, with equivalent representation of Vδ1 + and Vδ1 - cells, that are distinct from γδ T cells found in normal human tissues. These tumor-resident Vδ2 - T cells can express the transcriptional program of exhausted αβ CD8 + T cells as well as canonical markers of terminal T-cell exhaustion including PD-1, TIGIT and TIM-3. Although Vδ2 - γδ T cells have reduced IL-2 production, they retain expression of cytolytic effector molecules and co-stimulatory receptors such as 4-1BB.

Exhausted Vδ2 - γδ T cells are composed of three distinct populations that lack TCF7, are clonally expanded and express cytotoxic molecules and multiple Vδ2 - T-cell receptors. Human tumor-derived Vδ2 - γδ T cells maintain cytotoxic function and pro-inflammatory cytokine secretion in vitro. The transcriptional program of Vδ2 - T cells in pretreatment tumor biopsies was used to predict subsequent clinical responses to PD-1 blockade in patients with cancer.

Thus, Vδ2 - γδ T cells within the tumor microenvironment can contribute to antitumor efficacy.

论文信息

作者
Rancan C、Arias-Badia M、Dogra P、Chen B、Aran D、Yang H、Luong D、Ilano A
第一作者单位
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA.United States
通讯作者单位
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA, USA. lawrence.fong@ucsf.edu.United States
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Nature immunology2023 Apr
原文标识
PubMed 36928415 · DOI 10.1038/s41590-023-01448-7